KKR’s 12.6% Stake and Digital Dentistry Boost Bull Case for Henry Schein

Bull Thesis: Henry Schein Is Undervalued Amid Defensive Cash Flows and Growth Opportunities

Despite a 6.6% decline over the past year and recent downward momentum, Henry Schein’s (Nasdaq: HSIC) robust free cash flow, low valuation multiples and leadership in healthcare distribution position it for a rebound. The company’s strong balance sheet, recurring revenue model and strategic investments in digital dentistry create a margin of safety at current levels near $63.

Financial Health

Henry Schein’s most recent trailing-twelve-month (TTM) results and balance-sheet metrics (as of 10/27/2025) highlight a resilient, cash-generative business:

Metric	Value
Revenue (TTM)	$12.77 billion
Net Income (TTM)	$389 million
Diluted EPS (TTM)	$3.11
Profit Margin	3.05%
Return on Equity (TTM)	8.12%
Free Cash Flow (TTM)	$333 million
Cash on Hand (MRQ)	$145 million
Total Debt / Equity (MRQ)	68.5%
Trailing P/E	21.23×
Forward P/E (est.)	12.69×
PEG Ratio (5-yr expected)	1.49×
Price/Sales (TTM)	0.65×
Price/Book (MRQ)	2.32×
EV/EBITDA	12.04×

• Revenue Growth and Profitability Trends
– Sales reached $12.7 billion in 2024, reflecting an approximate 11.2% compound annual growth rate since the 1995 IPO.
– Although net margins hover near 3%, the recurring nature of consumables and supply-chain solutions provides predictable cash flows.

• Cash Flow Analysis
– Levered free cash flow of $333 million covers capital expenditures and debt service with room to fund targeted acquisitions.
– Limited cash on hand ($145 million) is offset by moderate leverage (D/E 68.5%), leaving scope for balance-sheet optimization.

• Debt Levels and Obligations
– Total debt represents roughly two-thirds of equity, but interest coverage remains healthy given steady EBITDA.
– No near-term debt maturities pose refinancing risk in the public filings to date.

Healthcare Distribution by The New York Public Library

Competitive Position

Henry Schein is the world’s largest distributor of healthcare solutions to office-based dental and medical practitioners, with operations in 33 countries and over 1 million customer relationships.

• Market Share and Industry Position
– Dominant share in dental supplies (~10% in the late 1980s, grown via ~200 acquisitions since 1989).
– Member of Fortune 500 and S&P 500, recognized 14 consecutive years as a World’s Most Ethical Company (Ethisphere).

• Competitive Advantages
– Scale: Centralized, automated distribution network stocking >300,000 products.
– Integrated solutions: More than 300 business, clinical, technology and supply-chain offerings.
– Customer stickiness: Consumable products and software (e.g., Dentrix Ascend) drive recurring revenue.

• Barriers to Entry
– High capital requirements for distribution centers and logistics.
– Extensive supplier and provider relationships built over decades.

• Industry Trends and Dynamics
– Shift towards cloud-based dental software and digital imaging opens cross-sell opportunities.
– Aging global populations and increased healthcare spending support steady consumables demand.

Management and Corporate Governance

• Leadership Track Record
– CEO Stanley Bergman has led since 1989, overseeing a sales increase from $29 million to $12.7 billion.
– Bergman will step down at the end of 2025 but remain Chairman, supporting a smooth succession.

• Strategic Initiatives
– Spin-off of animal-health business (2019) crystallized core dental/medical distribution.
– Recent acquisitions of Biotech Dental (France) and S.I.N Implant System (Brazil) expand digital dentistry portfolio.

• Corporate Culture and Employee Quality
– 25,000+ “Team Schein” members emphasize customer empathy and community programs (Practice Pink, Global Student Outreach).
– Low attrition and high employee engagement sustain operational excellence.

• Governance Practices
– No material legal judgments as of the latest SEC filings; opioid-related lawsuits against the company were dismissed in 2019.
– A significant 12.6% stake by KKR (Schedule 13D/A amendments in August 2025) may catalyze further governance improvements.

Risks and Opportunities

• Market Risks
– Recent strong downward momentum has driven the stock to its 52-week support near $63.00. A break below could trigger further downside.
– Competition from Patterson Companies and Benco Dental may pressure pricing in key markets.

• Operational Risks
– Cybersecurity breach in October 2023 exfiltrating 35 TB of data underscores IT vulnerability.
– Management transition at year-end 2025 introduces execution risk.

• Regulatory Risks
– Distribution of healthcare products is subject to FDA regulation and potential supply-chain disruptions from global events.

• Growth Opportunities
– Expansion of digital dentistry solutions and cloud-based practice management software.
– Further tuck-in acquisitions in underserved international markets.
– KKR’s involvement may unlock operational efficiencies and value creation.

TL;DR

Henry Schein’s share price near $63 trades at just 0.65× sales and a forward P/E of 12.7×, despite generating $333 million in free cash flow and holding a dominant market position in dental and medical distribution. While short-term momentum is negative and a CEO succession looms, the defensive recurring-revenue model, growth in digital dentistry, and potential operational improvements under KKR’s 12.6% stake argue that HSIC is undervalued at current levels, offering a compelling entry point for long-term investors.